rme-2022-0002 Supplementary Figures & Tables.docx

Abstract: 
Objective: To evaluate the long-term   safety and efficacy of adipose-derived mesenchymal stem cell (ADMSC) therapy   in the treatment of knee osteoarthritis (OA).
Methods: 329 participants with knee OA   underwent intra-articular ADMSC therapy. Participants were followed up for 24-months and were separated based   on radiological OA grade.
Results: Treatment was well tolerated   with no related serious adverse events. All participant groups reported   clinically and statistically significant pain improvement. Clinical outcome was not influenced by   patients’ age or BMI. 
Conclusion: ADMSC therapy is a safe   and long-lasting effective treatment option for knee OA with the potential to   delay total joint replacement. In   addition to the observed clinical benefits, ADMSC therapy promises to reduce   the global economic burden of OA. 
Supplementary materials: 
Table 1. Adverse Events associated with abdominal   lipoharvest procedure
Table 2. Adverse Events associated with ADMSC   therapy
Table 3. Non injection related Adverse Events documented   during the 24month period of follow-up
Figure 1. Whole cohort vs. non total joint   replacement cohort outcome analysis – NPRS
Figure 2. Whole cohort vs. non total joint   replacement cohort outcome analysis – WOMAC
Figure 3. OA compartment outcome analysis - WOMAC
Figure 4. Carrier media outcome analysis - NPRS
Figure 5. Carrier media outcome analysis - WOMAC
Figure 6. Linear regression analysis of BMI vs change   in baseline WOMAC
Figure 7. Linear regression analysis of age vs change in baseline WOMAC